Latest ArticlesTo explore the adjuvant treatment of chronic glomerulonephritis(CGN) with nephritis rehabilitation tablets, and its influence on peripheral mononuclear cell B7-1, soluble FMS-like tyrosine kinase(sFlt)-1 and renal fibrosis indicators.
A total of 120 CGN patients in our hospital from January 2021 to December 2024 were selected for the study. They were randomly divided into the experimental group and the control group by simple sorting method, with 60 cases in each group. Eventually, the number dropped to 55 cases in each group and was included in the data analysis. Both groups received basic treatment. The control group was treated with cyclophosphamide, while the experimental group was supplemented with nephritis rehabilitation tablets. The clinical efficacy, B7-1, sFlt-1, renal fibrosis indicators [cystatin C(CysC), transforming growth factor(TGF)-β1, fibronectin(FN)], serum creatinine(Scr), urinary protein(UP), time for improvement of clinical symptoms (time for disappearance of nausea, vomiting, edema and fatigue), and occurrence of adverse reactions of the two groups were compared.
The total effective rate of treatment in the experimental group was higher than that in the control group(92.73% vs. 78.18%, P<0.05). After treatment, the levels of B7-1, sFlt-1, CysC, TGF-β1, Scr,, BUN, β2-MG and CD8+ in both groups decreased compared with those before treatment, and the levels in the experimental group were lower than those in the control group(P<0.05).After treatment, the FN and CD4+ in both groups increased compared with those before treatment, and the experimental group was higher than the control group(P<0.05). The improvement time of clinical symptoms in the experimental group was shorter than that in the control group(P<0.05). There was no statistically significant comparison of the incidence of adverse reactions between the two groups(P>0.05).
In patients with CGN, the administration of nephritis rehabilitation tablets as an adjunct can help reduce the expression of B7-1, down-regulate the level of sFlt-1, and improve renal fibrosis.
To compare the efficacy of tenofovir propofol and entecavir in the treatment of chronic hepatitis B(CHB) and their effects on serum Golgi protein(GP)73 and hepatitis B virus(HBV)-RNA.
A total of 96 eligible CHB patients admitted to our hospital from September 2023 to January 2025 were selected and randomly divided into the observation group and the control group, with 48 cases in each group. The control group was treated with entecavir dispersible tablets, while the observation group was treated with tenofovir profol fumarate tablets. Both groups were treated for 28 weeks. The clinical efficacy, GP73, HBV-RNA, hepatitis B surface antigen, HBV-DNA levels, liver function, liver fibrosis and the occurrence of adverse reactions were compared between the two groups.
After treatment, there was a statistically significant difference in the total effective rate between the two groups(P<0.05). After treatment, the levels of GP73, HBV-RNA, hepatitis B surface antigen, HBV-DNA, alanine transaminase, aspartate transaminase, total bilirubin, laminin, procollagen type Ⅲ, type Ⅳ collagen, hyaluronic acid in the observation group were lower than those in the control group(P<0.05). There was no statistically significant difference in the occurrence of adverse reactions between the two groups(P>0.05).
Tenofovir propofol can effectively improve liver function in patients with CHB, has good safety, and has a good antiviral effect when used for a long time.
Small intestinal bacterial overgrowth(SIBO) is a clinical syndrome caused by an abnormal increase in the number of bacteria in the small intestine. Children have incomplete physiological functions and are more prone to the disease. The treatment of SIBO in children is rather complex, and the use of antibacterial drugs needs to fully consider both efficacy and safety. This paper reviewed the pathological mechanism, epidemiological characteristics, clinical manifestations, diagnostic methods and treatment strategies of SIBO in children, and evaluated the efficacy and safety of antibacterial drugs, aiming to provide references for clinical diagnosis and treatment.
The prevalence of sarcopenia in patients with chronic kidney disease(CKD) increases with age, seriously affecting the quality of life and prognosis of patients. In recent years, the combination of traditional Chinese and Western medicine in the treatment of sarcopenia has demonstrated significant advantages in clinical practice. Based on the epidemiology, understanding of traditional Chinese and Western medicine, pathogenesis and treatment progress of CKD-related sarcopenia, this paper reviewed the current application effects of traditional Chinese and Western medicine in CKD-related sarcopenia, aiming to provide new ideas for clinical treatment.
Doxorubicin, as a widely used anti-tumor drug, has significant cardiac toxicity that limits its clinical effectiveness and safety, making it a major challenge in cancer treatment. In recent years, more and more researches have focused on the potential role of traditional Chinese medicine in reducing doxorubicin-induced cardiotoxicity(DIC), especially by regulating the expression of microRNA(miRNA). This article summarized the relevant research on traditional Chinese medicine alleviating DIC by regulating miRNA expression, explored its molecular mechanisms and research progress, in order to provide theoretical basis and reference for the development of new cardiac protection strategies in the future.
Gastrointestinal stromal tumor is a common mesenchymal tumor in the gastrointestinal tract, mainly occurring in the elderly population. Imatinib, as a treatment for gastrointestinal stromal tumor of the first-line drugs, has remarkable efficacy, but its easy to be nuclease degradation in the body, leading to low bioavailability. Clinically, large doses of the drug are often required, which can lead to serious adverse reactions such as neutropenia, coagulation dysfunction and hepatotoxicity. Imatinib nanoparticles can effectively stimulate the activation of immune cells, reduce the infiltration of immunosuppressive cells, and reshape the immune microenvironment by regulating the tyrosine kinase receptor protein-related signaling pathways, thereby enhancing the anti-tumor immune effect. In addition, targeted drug nanoparticles can prolong the action time of imatinib in the body, providing the possibility of reducing the drug dosage.This article reviewed the relevant research on imatinib nanoformulations in recent years, aiming to provide scientific basis and theoretical support for the treatment of gastrointestinal stromal tumors with new soft drug nanoparticles modified by hyaluronic acid, and to offer references for the application of new clinical drugs in the future.
Drug-induced immunotherapy-related gastrointestinal toxicity has become a highly concerned issue in clinical treatment. The adverse reactions it causes, such as diarrhea, inflammation and mucosal damage, seriously affect the quality of life and therapeutic effect of patients. Non-coding RNA is a class of molecules that do not translate into proteins but have important biological functions. Previous studies have shown that non-coding RNA plays a key role in drug-induced immunotherapy-related gastrointestinal toxicity by regulating mechanisms such as gene expression, inflammatory response, oxidative stress, intestinal barrier function, and intestinal microbiota. This article systematically reviewed the mechanism of action of non-coding RNA in drug-induced immunotherapy-related gastrointestinal toxicity, providing a new perspective for a deeper understanding of the toxicity mechanism and improvement of therapeutic efficacy.
To analyze the changes of a tertiary hospital operation indicators before and after the reform of diagnosis related groups(DRG) payment.
The operation indicators of a tertiary hospital from January 2020 to December 2021 were extracted and divided into two groups according to the time node: before DRG payment reform and after DRG payment reform. The operation of the hospital was analyzed from service ability, medical efficiency, hospital medical quality and data quality. The inpatient expenses and structural changes were analyzed by using the degree of structural change and intermittent time series.
After the reform of DRG payment method, the proportion of relative weight>1 cases, the proportion of grade 4 operations, and the proportion of surgical patients in sample hospitals increased significantly. The proportion of high-rate cases, the incidence of complications and other indicators of surgical patients decreased significantly. Compared with before the reform, the average hospitalization cost decreased by 2270.90 yuan, and the slope after the implementation of the reform was -406.55(P=0.002), that is, the average monthly decrease was 406.55 yuan. Among them, the largest contribution rate of structural change was material cost, exhibiting a negative change(value of structure variation=-2.23%), and the contribution rate was 36.66%.
After the implementation of DRG payment, the efficiency of hospital medical service has been improved continuously and the effect of medical cost control has been obvious. It is suggested that the hospital optimize the management mode, strengthen the cost control, and strengthen the supervision and assessment.